Q1 should mark a solid start to FY 26, with radiopharma-led growth offsetting still-muted IP demand.
20 Apr 2026
Q1 preview: Medical to continue growth trajectory
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Q1 preview: Medical to continue growth trajectory
Eckert & Ziegler SE (EUZ:ETR) | 0 0 (-1.4%) | Mkt Cap: 188.4m
- Published:
20 Apr 2026 -
Author:
Simon Keller, CFA -
Pages:
12 -
Q1 should mark a solid start to FY 26, with radiopharma-led growth offsetting still-muted IP demand.